Abstract Details

Title Does First Year MRI and Clinical Activity Correlate with Long Term Clinical Response to Glatiramer Acetate in Multiple Sclerosis Patients?

Topic MS and Related Diseases

Presentation(s) P01 - (-)

Poster/Presentation
Number 194

Objective

Background BACKGROUND: Identifying "real word" early predictors for response to DMT's is desirable. New T2 hyperintense(T2H)brain MRI lesions during first year of Interferon treatment were associated with increased risk for disability progression after 3-5 years of therapy. GA's unique mechanism of action compared to interferon raise the consideration that MRI metrics after one year of GA therapy may have different significance.

Design/Methods DESIGN/METHODS: Retrospective chart review identified 148 eligible MS patients being on GA (>1 year) as their initial DMT. Patients with any previous significant exposure (>12 months) to immunosuppressants were excluded .Data included demographics, EDSS at baseline(0) and follow up while on GA, number and dates of relapses during the year preceding the start of GA and relapses during first year of GA therapy, time and reason for cessation of GA. Radiological data included baseline/follow-up yearly MRI's.

Results RESULTS: 133 female and 15 male patients [mean age 42.8 (0.9) years] had baseline EDSS(0) of 2.49 (1.6) and EDSS(1) (at 320±20 days) 2.48 (1.5). At baseline, 26.4% of patients had enhancing lesions (T1Gd+). Brain MRI(1) showed new T2H lesions in 26.4% and 13.1% T1Gd(+), while brain MRI(2) showed new T2H lesions in 21.8%, and 10% had T1Gd(+). Brain MRI(3) showed T2H in 10% and 3.7% T1Gd(+).EDSS over 5 years (N=144, 135, 112, 48 at 1, 2, 3, 5 years respectively) were noted to be stable for all patients [2.5(0) -2.7(5)].

Conclusions CONCLUSIONS: Patients on GA after one to two years harbor new brain MRI T1Gd(+) and T2H lesions, which decline over the third year. The significance of new and enhancing MRI lesions and their predictive value over 5 years of follow up will be presented.

Authors/Disclosures
Yuval Karmon, MD (Multiple Sclerosis Clinic) PRESENTER	No disclosure on file
Vittorio Martinelli (S. Raffaele Hospital)	Dr. Martinelli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis, Biogen, Sanofi Genzyme, TEVA and Merck. Dr. Martinelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck .
Murali Ramanathan, PhD (University At Buffalo)	The institution of Dr. Ramanathan has received research support from DoD. Dr. Ramanathan has received publishing royalties from a publication relating to health care.
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo)	Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.

��ɫ��

��ɫ��